India on Tuesday launched a low-cost, indigenously-manufactured Thalassemia and Sickle Cell diagnostic kit that will simplify the identification of seven common beta-thalassemia mutations and two common abnormal haemoglobins common in India. This kit, tailor-made for the Indian population, can also be used for screening.

The kit, to be made available at approximately Rs 400 in the public health facilities up to district levels, is expected to bring down the prices of the test in the open market where it costs up to Rs 15,000.